TEL AVIV, Israel--(BUSINESS WIRE)--Compugen Ltd. (NASDAQ:CGEN) announced today that CGEN-25017, a novel peptide antagonist of the Angiopoietin/Tie-2 pathway, has shown inhibitory effects in a model of angiogenesis. These initial results support the potential use of this novel peptide for the treatment of angiogenesis-related diseases, such as cancer, macular degeneration, diabetic retinopathy, psoriasis, arthritis, and atherosclerosis. The sequence and potential use of CGEN-25017 was first predicted in silico using Compugen’s DAC Blockers Platform, which was designed to predict peptides that block proteins of interest from achieving certain disease-associated conformations.
